JP2014521726A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521726A5 JP2014521726A5 JP2014525188A JP2014525188A JP2014521726A5 JP 2014521726 A5 JP2014521726 A5 JP 2014521726A5 JP 2014525188 A JP2014525188 A JP 2014525188A JP 2014525188 A JP2014525188 A JP 2014525188A JP 2014521726 A5 JP2014521726 A5 JP 2014521726A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- item
- less
- solvent system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 32
- 239000002904 solvent Substances 0.000 claims description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229910052763 palladium Inorganic materials 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- 238000001953 recrystallisation Methods 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002002 slurry Substances 0.000 claims 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 125000004431 deuterium atom Chemical group 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- HSARCAKRDFJMNW-UHFFFAOYSA-N 1-aminoethanesulfonic acid;2-aminoethanesulfonic acid Chemical compound CC(N)S(O)(=O)=O.NCCS(O)(=O)=O HSARCAKRDFJMNW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical group OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940116298 l- malic acid Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161522624P | 2011-08-11 | 2011-08-11 | |
| US61/522,624 | 2011-08-11 | ||
| PCT/US2012/050453 WO2013023184A1 (en) | 2011-08-11 | 2012-08-10 | Kinase inhibitor polymorphs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014521726A JP2014521726A (ja) | 2014-08-28 |
| JP2014521726A5 true JP2014521726A5 (OSRAM) | 2015-10-01 |
Family
ID=47669006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014525188A Pending JP2014521726A (ja) | 2011-08-11 | 2012-08-10 | キナーゼ阻害剤多形体 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20150065524A1 (OSRAM) |
| EP (1) | EP2741749A4 (OSRAM) |
| JP (1) | JP2014521726A (OSRAM) |
| KR (1) | KR20140079368A (OSRAM) |
| CN (1) | CN103957918A (OSRAM) |
| AU (1) | AU2012294202B2 (OSRAM) |
| BR (1) | BR112014003214A2 (OSRAM) |
| CA (1) | CA2844742A1 (OSRAM) |
| CL (1) | CL2014000343A1 (OSRAM) |
| CO (1) | CO6960542A2 (OSRAM) |
| CR (1) | CR20140082A (OSRAM) |
| DO (1) | DOP2014000027A (OSRAM) |
| EA (1) | EA027970B1 (OSRAM) |
| EC (1) | ECSP14013236A (OSRAM) |
| HK (1) | HK1199203A1 (OSRAM) |
| IL (1) | IL230850A0 (OSRAM) |
| MX (1) | MX2014001662A (OSRAM) |
| MY (1) | MY186267A (OSRAM) |
| PE (1) | PE20141358A1 (OSRAM) |
| PH (1) | PH12014500331A1 (OSRAM) |
| RU (1) | RU2636588C2 (OSRAM) |
| SG (2) | SG10201606288TA (OSRAM) |
| TN (1) | TN2014000063A1 (OSRAM) |
| WO (1) | WO2013023184A1 (OSRAM) |
| ZA (1) | ZA201401211B (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4903036B2 (ja) | 2003-01-06 | 2012-03-21 | アンジオケム・インコーポレーテッド | 血液脳関門を通過する担体としてのアプロチニンおよび類似体 |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| WO2010043047A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| CA2740317A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
| US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| AU2009327267A1 (en) | 2008-12-17 | 2011-07-14 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| ES2729261T3 (es) | 2009-04-20 | 2019-10-31 | Angiochem Inc | Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2 |
| WO2011000095A1 (en) | 2009-07-02 | 2011-01-06 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| HK1201828A1 (en) * | 2011-11-08 | 2015-09-11 | Intellikine, Llc | Treatment regimens using multiple pharmaceutical agents |
| CN104250250A (zh) * | 2013-06-25 | 2014-12-31 | 苏州科捷生物医药有限公司 | 4-芳香胺基嘧啶类化合物及其抗肿瘤用途 |
| JP2016537345A (ja) | 2013-11-13 | 2016-12-01 | ノバルティス アーゲー | 免疫応答を増強するためのｍＴＯＲ阻害剤 |
| CA3225453A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| FI3888674T3 (fi) | 2014-04-07 | 2024-07-02 | Novartis Ag | Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| BR112017001242A2 (pt) | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
| US20170209492A1 (en) | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| JP6919118B2 (ja) | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | ＧＦＲα−４キメラ抗原受容体を用いる癌の治療 |
| MY189028A (en) | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| CA2961636A1 (en) | 2014-09-17 | 2016-03-24 | Boris ENGELS | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| CN106973568B (zh) | 2014-10-08 | 2021-07-23 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| ES2876974T3 (es) | 2015-04-07 | 2021-11-15 | Novartis Ag | Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina |
| CN108473957B (zh) | 2015-04-17 | 2024-07-16 | 诺华股份有限公司 | 改善嵌合抗原受体表达细胞的功效和扩增的方法 |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| EP3307326B9 (en) | 2015-06-15 | 2021-02-24 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| ES2636646B1 (es) * | 2016-04-05 | 2018-08-03 | Universidade De Santiago De Compostela | NUEVOS VEHÍCULOS PARA LA TRANSFECCIÓN DE miRNAs |
| US11365252B2 (en) | 2016-07-20 | 2022-06-21 | University Of Utah Research Foundation | CD229 CAR T cells and methods of use thereof |
| EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
| WO2018095953A1 (de) | 2016-11-23 | 2018-05-31 | Bayer Cropscience Aktiengesellschaft | 2-[3-(alkylsulfonyl)-2h-indazol-2-yl]-3h-imidazo[4,5-b]pyridin-derivate und ähnliche verbindungen als schädlingsbekämpfungsmittel |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| ES2949908T3 (es) * | 2018-01-09 | 2023-10-03 | Halcyon Labs Private Ltd | Proceso para la preparación de Crisaborol y sus intermedios |
| US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW444018B (en) * | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
| US7420084B2 (en) * | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US8476431B2 (en) * | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| TWI546305B (zh) * | 2011-01-10 | 2016-08-21 | 英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
-
2012
- 2012-08-10 AU AU2012294202A patent/AU2012294202B2/en active Active
- 2012-08-10 PE PE2014000191A patent/PE20141358A1/es not_active Application Discontinuation
- 2012-08-10 KR KR1020147006105A patent/KR20140079368A/ko not_active Ceased
- 2012-08-10 SG SG10201606288TA patent/SG10201606288TA/en unknown
- 2012-08-10 US US14/238,426 patent/US20150065524A1/en not_active Abandoned
- 2012-08-10 JP JP2014525188A patent/JP2014521726A/ja active Pending
- 2012-08-10 MY MYPI2014000363A patent/MY186267A/en unknown
- 2012-08-10 EP EP12821708.0A patent/EP2741749A4/en not_active Withdrawn
- 2012-08-10 PH PH1/2014/500331A patent/PH12014500331A1/en unknown
- 2012-08-10 RU RU2014109023A patent/RU2636588C2/ru active
- 2012-08-10 EA EA201490446A patent/EA027970B1/ru not_active IP Right Cessation
- 2012-08-10 HK HK14112711.7A patent/HK1199203A1/xx unknown
- 2012-08-10 CA CA2844742A patent/CA2844742A1/en not_active Abandoned
- 2012-08-10 MX MX2014001662A patent/MX2014001662A/es unknown
- 2012-08-10 BR BR112014003214A patent/BR112014003214A2/pt not_active Application Discontinuation
- 2012-08-10 SG SG2014009492A patent/SG2014009492A/en unknown
- 2012-08-10 WO PCT/US2012/050453 patent/WO2013023184A1/en not_active Ceased
- 2012-08-10 CN CN201280043863.6A patent/CN103957918A/zh active Pending
-
2014
- 2014-02-06 IL IL230850A patent/IL230850A0/en unknown
- 2014-02-10 DO DO2014000027A patent/DOP2014000027A/es unknown
- 2014-02-11 TN TNP2014000063A patent/TN2014000063A1/en unknown
- 2014-02-11 CL CL2014000343A patent/CL2014000343A1/es unknown
- 2014-02-18 ZA ZA2014/01211A patent/ZA201401211B/en unknown
- 2014-02-20 CR CR20140082A patent/CR20140082A/es unknown
- 2014-03-11 CO CO14051879A patent/CO6960542A2/es unknown
- 2014-03-11 EC ECSP14013236 patent/ECSP14013236A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014521726A5 (OSRAM) | ||
| JP6439050B2 (ja) | Ａｓｋ１阻害剤を調製するプロセス | |
| JP7660040B2 (ja) | ３－（（１Ｒ，３Ｒ）－１－（２，６－ジフルオロ－４－（（１－（３－フルオロプロピル）アゼチジン－３－イル）アミノ）フェニル）－３－メチル－１，３，４，９－テトラヒドロ－２Ｈ－ピリド［３，４－ｂ］インドール－２－イル）－２，２－ジフルオロプロパン－１－オールの固体形態及び置換されたフェニル又はピリジニル部分を含む縮合三環式化合物を調製するための方法とそれらの使用方法 | |
| EP3464285B1 (en) | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | |
| RU2675851C2 (ru) | Кристаллические формы свободного основания | |
| WO2017008773A1 (en) | Crystalline forms of obeticholic acid | |
| US20240279228A1 (en) | Novel salts and crystals | |
| JP2009542787A5 (OSRAM) | ||
| WO2014093583A2 (en) | Synthetic methods for preparing 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, other salt forms of this compound and intermediates thereof | |
| WO2016011195A1 (en) | Th-302 solid forms and methods related thereto | |
| TW200538116A (en) | Process for the preparation of substituted triazole compounds | |
| JP2023078126A (ja) | 光学活性ジアザスピロ［４．５］デカン誘導体の分割 | |
| WO2011072383A1 (en) | Processes for the purification of lubiprostone | |
| WO2017221215A1 (en) | Salts of lenvatinib | |
| US20190194154A1 (en) | Polymorphic Forms Of Vortioxetine Hydrobromide Tert-Butanolate | |
| US20090197970A1 (en) | Crystalline form of cinacalcet | |
| JP2020535192A (ja) | レナリドミドの結晶形 | |
| US20150099753A1 (en) | Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine | |
| JP2020529972A (ja) | フェニルピリミドン化合物の塩、結晶多形並びにその医薬組成物及び使用 | |
| EP1913941A1 (en) | Polymorphic forms and solvates of Cinacalcet hydrochloride | |
| JP2024516199A (ja) | バルベナジンの合成方法 | |
| WO2015156428A1 (ko) | 비결정성 랄록시펜 염산염의 신규 제조방법 및이에 사용되는 신규 중간체 | |
| JP2013526573A5 (OSRAM) | ||
| JP2021531329A (ja) | ベンゾチオフェン化合物のマレイン酸塩、その結晶形式及びその用途 | |
| US20150158870A1 (en) | Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine |